Common manifestations of COVID-19 are respiratory and can extend from mild symptoms to
severe acute respiratory distress. The severity of the illness can also extend from mild …

The coronavirus disease 2019 (COVID-19) is currently representing a global health threat
especially for fragile individuals, such as cancer patients. It was demonstrated that cancer …

Background Patients with cancer have a higher risk of coronavirus disease 2019 (COVID‐
19) than noncancer patients. The authors conducted a multicenter retrospective study to …

The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in
most individuals, leading to COVID-19 disease. However, in some infected individuals, this …

Angiotensin-Converting Enzyme 2 (ACE2) has been proved to be the main host cell receptor
for the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …

The present review summarizes up-to-date evidence addressing the frequently discussed
clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer …

Highlights•Cancer care has been profoundly impacted by the global pandemic of COVID-19,
resulting in unprecedented challenges.•Oncology societies have updated guidelines for the …

Resumen VICENTE HERRERO, Mª Teofila; RAMIREZ INIGUEZ DE LA TORRE, Mª Victoria y
RUEDA GARRIDO, Juan Carlos. Vulnerability criteria for Covid-19 infection in workers. Rev …

Background Over 30 million COVID-19 cases have been diagnosed worldwide from late
2019. Among frail persons, cancer patients are at high risk of death from COVID-19 …

The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting …